Sonnet biotherapeutics provides fiscal year 2025 first quarter business and earnings update

Completion of son-1010 (il12-f h ab) monotherapy dose escalation in phase 1 sb101 trial; stable disease (sd) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the mtd, resulting in a partial response (pr)
SONN Ratings Summary
SONN Quant Ranking